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ABSTRACT
Introduction: Inadequately controlled asthma
is associated with increased healthcare resource
utilization. The eXpeRience registry was
initiated to evaluate real-world outcomes in
patients receiving omalizumab for uncontrolled
persistent allergic asthma. The current analysis
of data from the eXpeRience registry focuses on
healthcare resource utilization and on absences
from work or school.
Methods: The eXpeRience was a 2-year,
multinational, non-interventional,
observational registry conducted to investigate
real-world outcomes among patients receiving
omalizumab in accordance with country-
specific prescribing criteria for the treatment of
uncontrolled persistent allergic asthma.
Asthma-related healthcare resource utilization
(hospitalizations, emergency room visits or
unscheduled-asthma-related doctor visits or
interventions) and absences from work or
school were assessed pre-treatment (12-month
data were collected retrospectively at baseline)
and at months 12 and 24 after the initiation of
omalizumab treatment. Serious adverse event
(SAE) data were also assessed.
Results: A total of 943 patients (mean age
45 years; female 65%) were enrolled in the
registry. Overall, the mean (standard deviation
[SD]) number of asthma-related medical
healthcare uses per patient decreased from 6.2
(6.97) during the pre-treatment period to 1.0
(1.96) and 0.5 (1.28) at months 12 and 24,
respectively. The mean (SD) number of work or
school days missed due toasthmawas also lower at
months 12 (3.5 [17.28] and 1.6 [4.28], respectively)
and 24 (1.0 [4.66] and 1.9 [5.46], respectively)
compared with the pre-treatment period (26.4
[49.61] and 20.7 [27.49], respectively). The nature
and frequency of SAEs in the eXpeRience registry
were comparable to that seen in interventional
clinical trials with omalizumab.
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Asthma affects approximately, 300 million
individuals worldwide and places substantial
social and economic burdens on society [1, 2].
In the US, asthma was responsible for 456,000
hospitalizations, 1.75 million emergency room
(ER) visits and 13.9 million physician visits
annually between 2005 and 2009. In the same
period, patients with asthma missed 14.2
million work days and 10.5 million school
days per year [3]. Despite long-term treatment
with inhaled corticosteroids (ICS) and long-
acting b2-agonists (LABA), asthma remains
poorly controlled in a significant proportion of
patients [4]. Although poor compliance and
incorrect inhaler technique explains inadequate
disease control in some patients, many others
remain uncontrolled despite correction of these
factors [5].
Poorly controlled asthma doubles the mean
annual total asthma costs based on direct
(medication usage, unscheduled office visits,
ER visits, hospitalizations) and indirect (school/
work days lost) assessments, compared with
asthma that is partially or well-controlled [6].
The rates of hospitalizations, ER visits and
number of work/school days lost due to
asthma can be significantly reduced by
employing effective treatment strategies that
improve disease management [3].
Omalizumab is a humanized anti-
immunoglobulin E (IgE) monoclonal antibody
that is approved for the treatment of patients
with uncontrolled moderate-to-severe (US) or
severe (EU) persistent allergic (IgE-mediated)
asthma [7, 8]. The efficacy and safety of
omalizumab in patients with moderate and
severe allergic asthma have been demonstrated
in several randomized clinical trials [9–13] and
real-world clinical practice setting studies [14–
18]. These studies have shown that adjunctive
therapy with omalizumab significantly reduces
asthma exacerbations and improves asthma
control, lung function and asthma-related
quality of life, compared with placebo [9–13].
However, data on healthcare resource
utilization in patients with asthma are also
needed to provide information on the overall
burden of the disease, including cost [19].
Although several controlled clinical trials
have demonstrated that omalizumab reduced
the frequency of ER visits and asthma-related
hospitalizations [11, 20, 21], there is limited
corroborative evidence from real-world clinical
practice. The eXpeRience registry was initiated
to evaluate real-world outcomes in patients
receiving omalizumab for uncontrolled
persistent allergic asthma.
The primary results from eXpeRience have
been published previously [22], and indicate
that omalizumab is associated with
improvements in clinical outcomes such as
exacerbation rates and objective measures of
asthma control. The current analysis of data
from the eXpeRience registry focuses on
healthcare resource utilization and on
absences from work or school.
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METHODS
eXpeRience was a 2-year, multinational, non-
interventional, observational registry
established to collect data on the effectiveness
and safety of omalizumab therapy, prescribed
during routine clinical practice, in patients with
uncontrolled persistent allergic asthma.
The registry design has been described
previously [23]. Briefly, patients with
uncontrolled persistent allergic asthma were
recruited from 14 countries in Europe, North
America and Asia. Patients were required to
meet the local labeling requirements for
omalizumab use, and to have commenced
omalizumab within 15 weeks prior to
inclusion in the registry. Patients who had
received omalizumab within the previous
18 months, or who were concurrently enrolled
in a clinical trial for asthma medication, were
excluded.
At the time of a patient’s entry into the
registry, medical records were used to provide
information on endpoints of interest during the
year before omalizumab initiation. After entry
into the registry, data were collected
prospectively at *16 weeks and again at 8, 12,
18 and 24 months after initiation of
omalizumab treatment, with a minimum
requirement of two data collections per year.
Annualized data were calculated for month 12
(combining week 16, month 8 and month 12
time-points) and month 24 (combining month
18 and month 24 time-points). Treatment and
follow-up of patients was at the discretion of
treating physicians, who followed local medical
practice and labelling/reimbursement
guidelines.
In accordance with local regulations, the
registry design and amendments were reviewed
by independent ethics committees or
institutional review boards at each
participating center. All procedures followed
were in accordance with the Helsinki
Declaration of 1975, as revised in 2000 and
2008. Informed consent was obtained from all
patients for being included in the registry.
Assessments
Asthma-related healthcare resource utilization
and absences from work or school were
assessed pre-treatment (for the 12 months
prior to omalizumab treatment) and at
months 12 and 24 after the initiation of
omalizumab. The outcome measures
evaluated were: asthma-related
hospitalizations, ER visits and unscheduled
doctor visits; total medical healthcare use (a
composite of asthma-related hospitalizations,
ER visits and unscheduled doctor visits); and
number of missed work or school days due to
asthma.
Safety was assessed by recording the nature
and frequency of serious adverse events (SAEs)
that occurred during the registry.
Statistical Analysis
Data were analysed by Parexel International
GmbH (Berlin, Germany), in accordance with
the planned analysis. No formal statistical
hypotheses were tested; statistical analyses
were mainly descriptive. Disease background
and demographic variables were summarized
using mean and standard deviation (SD), and
frequencies for discrete variables. Descriptive
summaries are presented for healthcare resource
utilization.
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RESULTS
Patient Disposition and Baseline
Characteristics
A total of 943 patients were included in the
registry. Of these patients, 694 (73.6%)
completed the registry and 157 (16.6%)
discontinued; status was unknown for 92
(9.8%). Patients discontinued from the registry
for a variety of reasons, including: 52 (5.5%)
patients were lost to follow-up; 27 (2.9%)
patients withdrew their consent; 19 (2.0%)
patients stopped treatment due to a lack of
efficacy; 11 (1.2%) patients were non-compliant
or stopped treatment without reason; 9 (1.0%)
patients died during the registry timeline; 9
(1.0%) patients stopped treatment for
pregnancy-related reasons; 9 (1.0%) patients
stopped treatment due to adverse events; 7
(0.7%) patients moved away from the area
during the registry timeframe; 6 (0.6%)
stopped treatment due to financial reasons; 1
(0.1%) patient discontinued the registry at
month 18 with the primary reason for
discontinuation being 2 years follow-up period
completed before month 24; 1 (0.1%) patient’s
discontinuation reason was missing; and 6
(0.6%) patients discontinued treatment for
other reasons not specified.
Baseline characteristics have been described
previously [22]. In summary, patients had a
mean age of 45 years, were predominantly
female (65%), and had a median duration of
asthma of 16 years.
The intent-to-treat population (patients who
received at least one dose of omalizumab and
had at least one post-baseline efficacy
assessment) comprised 916/943 (97.1%)
patients; 27 patients were excluded due to lack
of post-baseline assessments. The safety
population (those who had received at least
one dose of omalizumab and had at least one
post-baseline safety assessment) comprised
925/943 (98.1%) patients.
Effect of Omalizumab on Asthma-related
Healthcare Resource Use
Annualized asthma-related hospitalizations, ER
visits and unscheduled doctor visits were lower
with omalizumab treatment at months 12 and
24 than during the pre-treatment period
(Fig. 1). In addition, the proportion of
patients with no annualized hospitalizations
(Fig. 2a), ER visits (Fig. 2b) or unscheduled
Fig. 1 Mean number of hospitalizations, ER visits and
unscheduled doctor visits per patient. Annualized data are
presented for month 12 (combining data from week 16,
month 8 and month 12 time-points) and month 24
(combining data from the month 18 and month 24 time-
points). * Within 12 months prior to the start of
omalizumab treatment. Error bars represent standard
deviation. ER emergency room
Fig. 2 (a) Asthma-related hospitalizations (excluding
patients with unknown status [pre-treatment n = 34;
month 12 n = 32; month 24 n = 15]), (b) ER visits
(excluding patients with unknown status [pre-treatment
n = 49 month 12 n = 34; month 24 n = 16]), and
(c) unscheduled doctor visits (excluding patients with
unknown status [pre-treatment n = 93; month 12 n = 50;
month 24 n = 24]). Annualized data are presented for
month 12 (combining data from week 16, month 8 and
month 12 time-points) and month 24 (combining data
from the month 18 and month 24 time-points). *Within
12 months prior to the start of omalizumab treatment. ER
emergency room
c
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doctor visits (Fig. 2c) was higher at months 12
and 24 compared with the pre-treatment
period.
Overall, the mean (SD) total number of
annualized asthma-related medical healthcare
uses (hospitalizations, ER visits and
unscheduled doctor visits) per patient
decreased from 6.2 (6.97) during the pre-
treatment period to 1.0 (1.96) and 0.5 (1.28) at
months 12 and 24, respectively. The proportion
of patients with no annualized asthma-related
medical healthcare use increased from 12.3%
(113/916) during the pre-treatment period to
60.2% (442/734) at month 12 and 75.4% (485/
643) at month 24.
Effect of Omalizumab on Work/School
Absence
The mean number of missed work or school
days due to asthma was lower at months 12 and
24 than during the pre-treatment period
(Fig. 3). The proportion of patients who did
not miss any work days due to asthma increased
from 16.4% (91/554) in the pre-treatment
period to 57.6% (234/406) and 71.1% (256/
360) at months 12 and 24, respectively.
Similarly, the proportion of patients who did
not miss any school days due to asthma was
13.1% (16/122) in the pre-treatment period,
66.7% (50/75) at month 12, and 64.0% (48/75)
at month 24.
Safety
Safety data have been described previously [22].
Briefly, 64 patients (6.9%) reported a total of
150 SAEs, with 28 reporting more than one SAE.
The most common SAE was asthma (32 patients
[3.5%]), followed by dyspnoea and pneumonia
(each in 7 patients [0.8%]). Nine deaths
occurred during the registry, none of which
were suspected to be related to omalizumab.
DISCUSSION
The results of this analysis of eXpeRience
registry data suggest that add-on treatment
with omalizumab is associated with reduced
asthma-related hospitalizations, ER visits and
unscheduled doctor visits in patients with
uncontrolled persistent allergic asthma. It also
demonstrated that the mean number of missed
work or school days due to asthma decreased
over 2 years of treatment with omalizumab
compared with the pre-treatment period.
Asthma remains poorly controlled in many
patients, leading to substantial financial burden
in the developed world [24]. Inadequately
controlled asthma is associated with increased
utilization of healthcare resources, incurring a
variety of direct (hospitalizations, ER visits,
physician/specialist consultations, medication
and laboratory tests) and indirect (e.g. absence
from work or school) costs [4, 25]. In Europe,
the total annual cost of asthma has been
Fig. 3 Mean number of work or school days missed per
patient. Annualized data are presented for month 12
(combining data from week 16, month 8 and month 12
time-points) and month 24 (combining data from the
month 18 and month 24 time-points). * Within
12 months prior to the start of omalizumab treatment.
Error bars represent standard deviation. ER emergency
room
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estimated at *€17.7 billion, of which *€9.8
billion is the indirect cost of lost productivity
due to absence from work [26]. Management of
persistent asthma has been estimated to incur
mean annual costs of €1,583 per patient, 37.5%
of which are direct ([50% for pharmacological
treatment and 25% for hospital services) and
62.5% of which are indirect (lost working days
or days with limited productivity) [27]. In
addition, productivity losses due to asthma
appear to be strongly associated with disease
severity [28].
Due to the high socioeconomic burden and
costs associated with healthcare resource use
among patients with uncontrolled asthma [29],
there is a need for interventions that have the
potential to prevent exacerbations and reduce
unscheduled healthcare contact. The results of
this analysis of eXpeRience registry data are
consistent with findings reported in clinical
trials [11, 13], observational studies [14, 16–18,
30, 31] and in analyses of healthcare insurance
claims [19]. In pivotal studies of omalizumab [9,
10, 12, 13], over 1,700 patients with moderate-
to-severe allergic asthma were treated with
omalizumab for 28–32 weeks. Taken as a
whole, these studies showed that omalizumab-
treated patients had significantly fewer
hospitalizations, ER visits and unscheduled
doctor visits than those receiving placebo [9,
10, 12, 13]. Furthermore, data from several
observational studies [14, 17, 32] also
corroborate the findings of the current
registry. These observational studies, which
included over 450 patients who received
omalizumab for up to 52 weeks, explored the
effectiveness of omalizumab as an add-on
therapy. In the PERSIST study [14], 58.7%
patients had fewer healthcare visits (a
composite of general practitioner visits,
specialist visits, ER visits and hospitalizations)
at the end of the treatment period compared
with the previous year. In two other studies [17,
32], annual hospitalization rates were found to
be 29–96% lower, and ER visits 65–87% lower,
after treatment with omalizumab. Additionally,
in a retrospective analysis of health insurance
claims, there were relative reductions of 40.8
and 48.6% in the rates of hospitalizations and
ER visits, respectively, between the pre- and
post-omalizumab treatment periods in patients
with uncontrolled asthma [19]. This analysis
also demonstrated significant reductions
(p\0.0001) in the mean number of ER visits
and hospitalizations after initiation of
omalizumab [19].
Similarly, several studies investigated the
effect of omalizumab on the absence from
work or school due to asthma [30, 33, 34]. In
one of these studies, work or school days missed
due to asthma was markedly reduced by 72.7
and 76.7% in patients aged C50 and \50 years,
respectively, after 4 months of omalizumab
treatment (p\0.001) [33]. Treatment with
omalizumab also led to a significant decrease
in the mean number of work days lost in a study
by Costello and colleagues [30]. In a double-
blind randomized controlled study in children
there was a significantly lower mean number of
absences from school in children receiving
omalizumab, in comparison with placebo, over
the entire treatment period (p = 0.04) [34]. The
results of the current, real-world analysis
confirm and extend these findings, as over a
2-year period, the mean number of missed work
or school days due to asthma decreased with
omalizumab treatment compared with the pre-
treatment period.
Data from clinical trials [11, 20, 35] and
previously reported results from the eXpeRience
registry [22] have shown that omalizumab is
associated with reductions in exacerbations and
with improvements in asthma control and
symptoms. Marked reductions in oral
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corticosteroid use in patients receiving
omalizumab have also been observed [22].
Asthma exacerbations are indicative of poor
disease control [36]. Since uncontrolled asthma
is associated with more exacerbations and
healthcare visits versus controlled asthma [6,
29, 37, 38], a reduction in exacerbations would
be expected to lead to a reduction in
hospitalizations, ER visits and unscheduled
doctor visits while simultaneously improving
health-related quality of life [29, 39]. Similarly,
better asthma control and reduced symptoms
might be expected to improve attendance at
school or work [1].
Although lack of efficacy was seen in 19
patients, in the worst case scenario, even if
‘‘non-compliant/stopping treatment without
reason’’ and ‘‘AE related’’ can be considered as
lack of efficacy, this percentage of patients is
still relatively low (total n = 39; 4.1%).
Assuming the number of hospitalizations for
those 39 patients at month 12 (in addition to
702 patients analysed) remained same as the
average number of hospitalizations at pre-
treatment visit (0.7, Fig. 1), the number of
hospitalizations at month 12 would only
increase by 0.04 per patient per annum. This
increment would not influence the overall
annualized hospitalization reduction effect of
omalizumab in the registry population.
We therefore propose that the effects on
healthcare resource use and on absence from
work or school observed in the eXpeRience
registry might reasonably be attributed to the
positive impact of omalizumab treatment on
exacerbations and asthma control. However,
we also recognize that caution is warranted in
interpreting the results from the eXpeRience
registry, given its open-label, observational
design; our findings may be partly
attributable to factors other than the
treatment of interest. Other possible
limitations include patient selection criteria
and the retrospective nature of pre-enrolment
data collection.
CONCLUSIONS
To our knowledge, eXpeRience is the largest
multinational study of real-world outcomes in
patients receiving omalizumab for the
treatment of allergic asthma. With the caveats
noted above, we conclude that, in the real-
world setting, treatment with omalizumab is
associated with reductions in healthcare
resource utilization and absence from work or
school when added to current therapy in
patients with uncontrolled persistent allergic
asthma. The findings from the registry
supplement the findings from the omalizumab
clinical trial program and are likely to be
relevant to the impact of omalizumab on the
direct and indirect costs of healthcare and
reducing socioeconomic burden of patients
with uncontrolled allergic asthma.
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